MEDIA RELEASE

23rd September 2014

Animal testing can mislead drug discovery and development

Several blockbuster drugs would not be on the market, if scientists had relied solely on drug-uptake in animal trials, according to new research.

Humane Research Australia applauds the work of PharmaInformatic, a German biotech company, which has compared study results on drug-uptake ("Oral Bioavailability") in animals and humans for a large number of approved and established drugs.

Results from the German study have shown that oral bioavailability in animals is inconsistent with the values reported for humans and large differences can exist. This also applies to very successful commercial drugs, called blockbuster drugs, with annual sales of more than one billion US Dollar.

In drug development today, a large number of compounds are tested in animals, such as rats, dogs, monkeys and mice to determine whether they are effective and possess sufficient oral bioavailability. If bioavailability in animals is too low, further drug development is usually discontinued.

Last year, HRA revealed an Australian example of animals used in this type of drug testing. Beagles undergo pharmaceutical drug tests

However, drug-uptake studies in animals can be misleading: Aripiprazole and Esomeprazole, the most sold drugs of 2013, have low oral bioavailability in animals, but drug-uptake in humans is high.

Alternative computational methods, such as the expert system IMPACT-F replace animal trials on drug-uptake.

Pharmaceutical companies have applied the expert system to evaluate human oral bioavailability in various therapeutic areas such as diabetes, inflammation, antivirals, autoimmune diseases and cancer.

The expert system evaluates oral bioavailability in humans significantly more reliably than animal trials. This further increases the prospects of human clinical trials, because the optimum oral dose for first-in-human clinical trials can be determined much more accurately. Efficacy issues are identified as the main reason why clinical trials fail.

Images available at:

Contact:
Dr. Wolfgang Boomgaarden, phone: +49.4921.993360
PharmaInformatic Boomgaarden, Friesenstr. 36, 26721 Emden, Germany, http://www.pharmainformatic.com

Further detailed information: